Clinical Trial Update: Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating markers to predict response to a combined therapy in HER2-positive breast cancer, terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Carcinoma Ductal Breast

Snippet

Sponsor: West German Study Group | Conditions: Carcinoma, Ductal, Breast | Phase 2 | Status: TERMINATED | Results posted: 2019-09-17